Corrigendum to ‘A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody’

The authors regret to advise that the data for the number of patients who experienced paronychia (G1/2 shown in Table 3 is incorrect. The number of patients who experienced paronychia (G1/2) was 12, therefore 34% (12/35) is correct.

The authors would like to apologise for any inconvenience caused.